Gioia C. Sha
YOU?
Author Swipe
View article: Supplementary Figure 2 from BCL-2 Family Inhibition Enhances mTORC1/2 Inhibition in <i>PIK3CA</i>-Mutant Colorectal Cancer
Supplementary Figure 2 from BCL-2 Family Inhibition Enhances mTORC1/2 Inhibition in <i>PIK3CA</i>-Mutant Colorectal Cancer Open
Supplementary Figure 2. Navitoclax enhances the responses of copanlisib in murine and human CRC lines.
View article: Data from MTORC1/2 Inhibition as a Therapeutic Strategy for <i>PIK3CA</i> Mutant Cancers
Data from MTORC1/2 Inhibition as a Therapeutic Strategy for <i>PIK3CA</i> Mutant Cancers Open
PIK3CA mutations are common in clinical molecular profiling, yet an effective means to target these cancers has yet to be developed. MTORC1 inhibitors are often used off-label for patients with PIK3CA mutant cancers with only…
View article: Supplementary Figure S1 from MTORC1/2 Inhibition as a Therapeutic Strategy for <i>PIK3CA</i> Mutant Cancers
Supplementary Figure S1 from MTORC1/2 Inhibition as a Therapeutic Strategy for <i>PIK3CA</i> Mutant Cancers Open
Supplementary Figure S1 presents the viability of SW48 and SW48PK cells after treatment with BEZ235 and TAK-228 at the 100-400nM concentrations.
View article: Supplementary Table S1 from MTORC1/2 Inhibition as a Therapeutic Strategy for <i>PIK3CA</i> Mutant Cancers
Supplementary Table S1 from MTORC1/2 Inhibition as a Therapeutic Strategy for <i>PIK3CA</i> Mutant Cancers Open
Supplementary Table S1 compares the intestinal tumor counts and percent of tumors progressing to cancer for mouse models with activating alterations in PIK3CA.
View article: Data from MTORC1/2 Inhibition as a Therapeutic Strategy for <i>PIK3CA</i> Mutant Cancers
Data from MTORC1/2 Inhibition as a Therapeutic Strategy for <i>PIK3CA</i> Mutant Cancers Open
PIK3CA mutations are common in clinical molecular profiling, yet an effective means to target these cancers has yet to be developed. MTORC1 inhibitors are often used off-label for patients with PIK3CA mutant cancers with only…
View article: Supplementary Table S1 from MTORC1/2 Inhibition as a Therapeutic Strategy for <i>PIK3CA</i> Mutant Cancers
Supplementary Table S1 from MTORC1/2 Inhibition as a Therapeutic Strategy for <i>PIK3CA</i> Mutant Cancers Open
Supplementary Table S1 compares the intestinal tumor counts and percent of tumors progressing to cancer for mouse models with activating alterations in PIK3CA.
View article: Supplementary Figure S1 from MTORC1/2 Inhibition as a Therapeutic Strategy for <i>PIK3CA</i> Mutant Cancers
Supplementary Figure S1 from MTORC1/2 Inhibition as a Therapeutic Strategy for <i>PIK3CA</i> Mutant Cancers Open
Supplementary Figure S1 presents the viability of SW48 and SW48PK cells after treatment with BEZ235 and TAK-228 at the 100-400nM concentrations.
View article: Impact of baseline culture conditions of cancer organoids when determining therapeutic response and tumor heterogeneity
Impact of baseline culture conditions of cancer organoids when determining therapeutic response and tumor heterogeneity Open
View article: Impact of baseline culture conditions of mouse-derived cancer organoids when determining therapeutic response and tumor heterogeneity
Impact of baseline culture conditions of mouse-derived cancer organoids when determining therapeutic response and tumor heterogeneity Open
Representative models are needed to screen new therapies for patients with cancer. Cancer organoids are a leap forward as a culture model that faithfully represents the disease. Mouse-derived cancer organoids (MDCOs) are becoming increasin…
View article: MTORC1/2 Inhibition as a Therapeutic Strategy for <i>PIK3CA</i> Mutant Cancers
MTORC1/2 Inhibition as a Therapeutic Strategy for <i>PIK3CA</i> Mutant Cancers Open
PIK3CA mutations are common in clinical molecular profiling, yet an effective means to target these cancers has yet to be developed. MTORC1 inhibitors are often used off-label for patients with PIK3CA mutant cancers with only limited data …